Российское респираторное общество

Критерии оценки качества медицинской помощи 
№ 
 
Критерии качества 
Уровень 
достоверности 
доказательств 
Уровень 
убедительности 
рекомендаций 
Этап постановки диагноза
1 
Выполнен общий физикальный осмотр 
2 
Выполнена спирометрия с бронходилатационным 
тестом 
3 
Выполнена оценка симптомов по шкале mMRC 
или CAT 
4 
Выполнена рентгенография органов грудной 
клетки 
5 
Выполнен общий анализ крови с подсчетом 
лейкоцитарной формулы 
6 
Выполнена КТ органов грудной клетки при 
наличии показаний 
7 
8 
9 
10
Лечение стабильной ХОБЛ 
1 
Выполнено назначение комбинации ДДАХ/ДДБА 
пациенту с выраженными симптомами
2 
Выполнено 
назначение 
бронходилататора 
длительного действия пациенту с легкими 
симптомами 
3 
Проведена 
оценка 
симптомов 
и 
частоты 
обострений через … месяцев
4 
Выполнена спирометрия через 1 месяц 
Лечение обострения ХОБЛ 
1 
 
2 
3 
4 
5 
6 
7 
8 

Список литературы 
1.
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 
Revised 2016 // www.goldcopd.com. 
2.
Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society 
public policy statement: novel risk factors and the global burden of chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693–718.
3.
Lamprecht B, McBurnie MA, Vollmer WM, et al., BOLD Collaborative Research Group: 
COPD in never smokers: results form the population-based burden of obstructive lung 
disease study. Chest 2011; 139: 752–763. 
4.
Mehta AJ, Miedinger D, Keidel D. et al., The SAPALDIA Team. Occupational exposure 
to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the 
Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am J 
Respir Crit Care Med 2012; 185: 1292– 1300.
5.
Silva GE, Sherrill DL, Guerra S et al. Asthma as a risk factor for COPD in a longitudinal 
study. Chest 2004; 126: 59–65.
6.
Stoller JK: Clinical features and natural history of severe alpha-1-antitrypsin deficiency. 
Chest 1997; 111: 123S–128S.
7.
Stoller JK, Aboussouan LS: A review of alpha- 1-antitrypsin deficiency. Am J Respir 
Crit Care Med 2012; 185: 246–259.
8.
Smolonska J, Wijmenga C, Postma DS, Boezen HM: Meta-analyses on suspected chronic 
obstructive pulmonary disease genes: a summary of 20 years’ research. Am J Respir Crit 
Care Med 2009; 180: 618–631.
9.
Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, Russi EW, 
Ackermann-Liebrich U, Leuenberger P: Bronchial hyperresponsiveness and the 
development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort 
study. Thorax 2006; 61: 671–677.
10.
de Marco R, Accordini S, Marcon A, Cerveri I, Antó JM, Gislason T, Heinrich J, Janson 
C, Jarvis D, Kuenzli N, Leynaert B, Sunyer J, Svanes C, Wjst M, Burney P, European 
Community Respiratory Health Survey (ECRHS): Risk factors for chronic obstructive 
pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 
2011; 183: 891–897.
11.
de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, 
Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich 

J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P: Incidence of chronic 
obstructive pulmonary disease in a cohort of young adults according to the presence of 
chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175: 32–39.
12.
Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T: 
Long-term decline in lung function, utilisation of care and quality of life in modified 
GOLD stage 1 COPD. Thorax 2008; 63: 768– 774.
13.
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 
Revised 2011 // www.goldcopd.com. 
14.
Celli B, MacNee W, ATS/ERS Task Force: Standards for the diagnosis and treatment of 
patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J 2004; 23: 
932–946.
15.
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the 
Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients 
with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–586.
16.
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N: Development and 
first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648–654.
17.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, 
Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: 
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 
2010; 363: 1128–1138.
18.
Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 
2009; 33: 1165–1185.
19.
Celli B, Cote C, Marin J, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, 
Cabral HJ: The body mass index, airflow obstruction, dyspnea, and exercise capacity 
index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012. 
20.
Global Strategy for Asthma Management and Prevention. Revised 2016 // 
www.ginasthma.com. 
21.
Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C et al. Bronchodilator 
responsiveness in patients with COPD. Eur Respir J 2008;31:742–50.
22.
Albert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P et al. Bronchodilator 
responsiveness as a phenotypic characteristic of established chronic obstructive 
pulmonary disease. Thorax 2012;67:701–8. 

23.
Broekhuizen BD, Sachs AP, Moons KG, Cheragwandi SA, Damste HE, Wignands GJ et 
al. Diagnostic value of oral prednisolone test for chronic obstructive pulmonary 
disorders. Ann Fam Med 2011;9:104–9.
24.
Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable 
chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991;114:216–
23.
25.
Woolcock AJ. Corticosteroid-resistant asthma. Definitions. Am J Respir Crit Care Med 
1996;154:S45–8.
26.
Waschki B, Kirsten A, Holz O. et al. Physical activity is the strongest predictor of all-
cause mortality in patients with COPD: a prospective cohort study. Chest 2011;140:331–
42. 
27.
Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory 
Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 
2006;173:1390-413.
28.
Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint 
ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007;131:4S-42S.
29.
Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. 
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary 
disease. Cochrane Database Syst Rev 2011 Oct 5;(10):CD005305. 
30.
Mahler DA. Pulmonary rehabilitation. Chest 1998;113:263S-8S. 
31.
Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:19-38.
32.
Belman MJ, Botnick WC, Nathan SD, Chon KH. Ventilatory load characteristics during 
ventilatory muscle training. Am J Respir Crit Care Med 1994;149:925-9
33.
Puhan MA, Busching G, Schunemann HJ, VanOort E, Zaugg C, Frey M. Interval versus 
continuous high-intensity exercise in chronic obstructive pulmonary disease: a 
randomized trial. Ann Intern Med 2006;145:816-25.
34.
O’Brien K, Geddes EL, Reid WD, Brooks D, Crowe J. Inspiratory muscle training 
compared with other rehabilitation interventions in chronic obstructive pulmonary 
disease: a systematic review update. J Cardiopulm Rehabil Prev 2008;28:128-41. 
35.
Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 
1995;152:861-4. 
36.
Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA 
Jr, Enright PL, Kanner RE, O’Hara P: Effects of smoking intervention and the use of an 

inhaled anticholinergic bronchodilator on the rate of decline of FEV 1 . The Lung Health 
Study. JAMA 1994; 272: 1497–1505. 
37.
Heffner JE, Fahy B, Hilling L, Barbieri C: Outcomes of advance directive education of 
pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055–1059.
38.
Stewart MA: Effective physician-patient communication and health outcomes: a review. 
CMAJ 1995; 152: 1423–1433.
39.
Bischoff EW, Hamd DH, Sedeno M, Benedetti A, Schermer TR, Bernard S, Maltais F, 
Bourbeau J: Effects of written action plan adherence on COPD exacerbation recovery. 
Thorax 2011; 66: 26–31.
40.
Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Toumilehto J, Nissinen A: 
Smoking cessation, decline in pulmonary function and total mortality: a 30-year follow-
up study among the Finnish cohorts of the Seven Countries Study. Thorax 2001; 56: 703– 
707.
41.
Chandler MA, Rennard SI: Smoking cessation. Chest 2010; 137: 428–435.
42.
Henningfield JE: Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 
1196–1203.
43.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, 
Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of 
sustained- release bupropion, a nicotine patch, or both for smoking cessation. N Engl J 
Med 1999; 340: 685–691.
44.
Silagy C, Mant D, Fowler G, Lodge M: Metaanalysis on efficacy of nicotine replacement 
therapies in smoking cessation. Lancet 1994; 343: 139–142.
45.
Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, 
Patel MK, Jamerson B: Smoking cessation in patients with chronic obstructive 
pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 
357: 1571–1575.
46.
Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA: Smoking 
cessation interventions in COPD: a network metaanalysis of randomised trials. Eur 
Respir J 2009; 34: 634–640.
47.
Faessel H, Ravva P, Williams K: Pharmacokinetics, safety, and tolerability of varenicline 
in 
healthy 
adolescent 
smokers: 
a 
multicenter, 
randomized, 
double-blind, 
placebocontrolled, parallel-group study. Clin Ther 2009; 31: 177–189.
48.
Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;1:CD002733.

49.
Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for 
preventing pneumococcal infection in patients with chronic obstructive pulmonary 
disease. Cochrane Database Syst Rev 2010;11:CD001390. 
50.
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on 
outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a 
prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171–8. 
51.
Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT et al. Efficacy 
of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary 
disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 
2009;10:59. 
52.
Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung 
hyperinflation in COPD. Prim Care Respir J 2013;22:101–11.
53.
O’Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B et al. Effects of 
tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir 
J 2004;23:832–40.
54.
Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response 
to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary 
disease. A three-center study. Am Rev Respir Dis 1989;139:1188–91.
55.
Higgings BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and 
ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic 
bronchitis. Eur Respir J 1991;4:415–20.
56.
O’Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term 
prospective assessment of home nebulizer treatment. Respir Med 1992;86:317–25.
57.
Sestini P, Renzoni E, Robinson S, Poole P, Ram FSF. Short-acting beta2-agonists for 
stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 
2002;3:CD001495. 
58.
Chung VCH, Ma PHX, Hui DSC, Tam WWS, Tang JL. Indacaterol for chronic 
obstructive pulmonary disease: systematic review and meta-analysis. PLoS ONE 
2013;8:e70784.
59.
Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M et al. 
Comparative efficacy of long-acting bronchodilators for COPD – a network meta-
analysis. Respir Res 2013;14:100.
60.
Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC et al. Lung 
function efficacy and symptomatic benefit of olodaterol once daily delivered via 
Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: 

results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014;9:697–
714.
61.
Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G et al. Efficacy and 
safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium 
monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: 
results from two multicenter, blinded, randomized controlled trials. Lancet Respir Med 
2014;2:472–86. 
62.
Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention 
of exacerbations in COPD // N Engl J Med 2011;364:1093–103.
63.
Decramer ML, Chapman KR, Dahl R et al., INVIGORATE investigators. Once-daily 
indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary 
disease (INVIGORATE): a randomised, blinded, parallel-group study // Lancet Respir 
Med. 2013; 1 (7): 524-33.
64.
Decramer ML, Hanania NA, Lotvall JO, Yawn BP. The safety of long-acting b2-agonists 
in the treatment of stable chronic obstructive disease. Int J Chron Obstruct Pulmon Dis 
2013;8:53–64. 
65.
Kew KM, Mavergames C, Walters JAE. Long-acting beta2-agonists for chronic 
obstructive pulmonary disease. Cochrane Database Syst Rev 2013;Art. No.:CD010177.
66.
Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk 
of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 
2012;142:305–11. 
67.
Kankaanranta H, Harju T, Kilpeläinen M et al. Diagnosis and pharmacotherapy of stable 
chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol 
Toxicol. 2015; 116 (4): 291-307. 
68.
Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive 
pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285. 
69.
Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic 
obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011;6:457–66.
70.
Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for 
chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J 
Chron Obstruct Pulmon Dis 2012;7:673–8.
71.
Jones PW, Rennard SI, Agusti A et al. Efficacy and safety of once-daily aclidinium in 
chronic obstructive pulmonary disease. Respir Res 2011;12:55.

72.
Kerwin E, Hebert J, Gallagher N et al. Efficacy and safety of NVA237 versus placebo 
and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40:1106–
14.
73.
Donohue JF, Niewoehner D, Brooks J et al. Safety and tolerability of once-daily 
umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic 
obstructive pulmonary disease: results from a 52-week, randomized, doubleblind, 
placebo-controlled study. Respir Res 2014;15:78. 
74.
Sharafkhaneh A, Majid H, Gross NJ. Safety and tolerability of inhalational 
anticholinergics in COPD. Drug Healthc Patient Saf 2013;5:49–55.
75.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al. A 4-year trial of 
tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–54.
76.
Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat inhaler and the risk of death 
in COPD. N Engl J Med 2013;369:1491–501.
77.
Appleton S, Jones T, Poole P et al. Ipratropium bromide versus short acting beta-2 
agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 
2006;2:CD001387.
78.
Appleton S, Jones T, Poole P et al. Ipratropium bromide versus long-acting beta-2 
agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 
2006;3:CD006101.
79.
Karner C, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either 
tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. 
Cochrane Database Syst Rev 2012;4:CD008989. 
80.
Decramer M, Anzueto A, Kerwin E et al. Efficacy and safety of umeclidinium plus 
vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in 
patients with chronic obstructive pulmonary disease: results from two multicenter, 
blinded, randomized controlled trials. Lancet Respir Med 2014;2:472–86.
81.
Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilation with QVA149 versus 
single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484–94.
82.
Donohue JF, Maleki-Yazdi MR, Kilbride S et al. Efficacy and safety of once-daily 
umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538–46.
83.
Vincken W, Aumann J, Chen H et al. Efficacy and safety of coadministration of once-
daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the 
GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014;9:215–28.

84.
Wedzicha JA, Dahl R, Buhl R et al. Pooled safety analysis of the fixed-dose combination 
of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium 
versus placebo in COPD patients. Respir Med 2014;108:1498–507.
85.
Ulrik CS. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and 
indacaterol once daily in patients with chronic obstructive pulmonary disease: a 
systematic review. Int J Chron Obstruct Pulmon Dis 2014;9:331–8.
86.
Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose 
combination versus mono-components in COPD (GOLD 2–4) // Eur Respir J. 2015; 45: 
969–979. 
87.
Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically 
meaningful improvements in quality of life // Respir. Med. 2015; 109 (10): 1312-9. 
88.
Beeh K.M., Westerman J., Kirsten A.M. et al. The 24-h lung-function profile of once-
daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary 
disease // Pulm Pharmacol Ther. 2015; 32: 53-9. 
89.
Wedzicha JA, Banerji D, Chapman KR et al.; FLAME Investigators.. Indacaterol-
Glycopyrronium versus Salmeterol-Fluticasone for COPD // N Engl J Med. 2016; 374 
(23): 2222-34. 
90.
Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary 
disease exacerbations with the dual bronchodilator QVA149 compared with 
glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group 
study. Lancet Respir Med 2013;1:199–209.
91.
Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic 
obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991. 
92.
Vestbo J, Anderson JA, Brook RD et al.; SUMMIT Investigators. Fluticasone furoate and 
vilanterol and survival in chronic obstructive pulmonary disease with heightened 
cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.. Lancet. 
2016; 387 (10030): 1817-26. 
93.
Calverley PMA, Anderson AMA, Ferguson GT et al. Salmeterol and fluticasone 
propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 
2007;356:775–89. 
94.
Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: 
systematic review and meta-analysis of randomised controlled trials and observational 
studies. Thorax 2011;66:699–708. 

95.
Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting 
beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. 
Cochrane Database Syst Rev 2007;4:CD003794. 
96.
Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of 
serious pneumonia. Thorax 2013;68: 1029–36. 
97.
Janson C, Larsson K, Lisspers KH, St€allberg B, Stratelis G, Goike H et al. Pneumonia 
and pneumonia related mortality in patients with COPD treated with fixed combinations 
of inhaled corticosteroids and long acting b2 agonist: observational matched cohort study 
(PATHOS). Br Med J 2013;346: f3306. 
98.
Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive 
pulmonary disease. Cochrane Database Syst Rev 2014;Art. No.:CD010115. 
99.
Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and 
progression. Am J Med 2010;123:1001–6. 
100.
Wedzicha JA, Calverley PMA, Seemungal TA et al. The prevention of chronic 
obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or 
tiotropium bromide. Am J Respir Crit Care Med 2008;177:19–26. 
101.
Watz H, Tetzlaff K, Wouters EF et al. Blood eosinophil count and exacerbations in 
severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: 
a post-hoc analysis of the WISDOM trial // Lancet Respir Med. 2016; 4(5): 390-8. 
102.
Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R et al. 
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for 
treatment of chronic obstructive pulmonary disease: a randomised trial. Ann Intern Med 
2007;146:545–55.
103.
Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T et al. 
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741– 50.
104.
Cazzola M, Ando F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A et al. A pilot 
study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium 
to the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol 
Ther 2007;20:556–61.
105.
Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in 
addition to tiotropium versus tiotropium or combination alone for chronic obstructive 
pulmonary disease. Cochrane Database Syst Rev 2011;3:CD008532. 
106.
Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic 
obstructive pulmonary disease. Cochrane Database Syst Rev 2011;5:CD002309. 

107.
Calverley PMA, Rabe KF, Goehring U-M et al. Roflumilast in symptomatic chronic 
obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685–94. 
108.
Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic 
obstructive pulmonary disease. Cochrane Database Syst Rev 2005;3:CD005374. 
109.
Schols AMWJ, Wesseling G, Kester ADM et al. Dose dependent increased mortality 
risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001;17:337–42.
110.
Man WD-C, Kemp P, Moxham J, Polkey MI. Skeletal muscle dysfunction in COPD: 
clinical and laboratory observations. Clin Sci (Lond) 2009;117:251–64. 
111.
Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013;188:901–6.
112.
Ram FS, Jones P, Jardim J, Castro AA, Atallah AN, Lacasse Y et al. Oral 
theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 
2002;3:CD003902.
113.
Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J et al. Comparison 
of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release 
theophylline in the treatment of COPD. Chest 2002;121:1058–69.
114.
Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S et al. Positive benefits of theophylline 
in a randomized, double-blind, parallelgroup, placebo-controlled study of low-dose, 
slow-release theophylline in the treatment of COPD for 1 year. Respirology 
2006;11:603–10.
115.
Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. A metaanalysis on the 
prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in 
patients with chronic obstructive pulmonary disease. Respir Med 2013;107:1385–92.
116.
Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations 
of COPD. N Engl J Med 2011;365:689–98. 
117.
Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic 
obstructive pulmonary disease. Cochrane Database Syst Rev 2012;8:CD001287. 
118.
Laube BL, Janssens HM, de Jongh FH et al. What the pulmonary specialist should 
know about the new inhalation therapies. Eur Respir J 2011;37:1308–31.
119.
Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the 
frequency of handling errors? Respiration 2008;75:18–25.
120.
Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur 
Respir Rev 2005;14:117–22.
121.
White P, Thorntoh H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of 
COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional 
observational study. PLoS ONE 2013;8:e75221.

122.
Rossi A, Guerriero M, Corrado A; OPTIMO/AIPO Study Group. Withdrawal of 
inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-
life study on the appropriateness of treatment in moderate COPD patients (OPTIMO) // 
Respir Res. 2014;15: 77. 
123.
Magnussen H, Disse B, Rodriguez-Roisin R et al. Withdrawal of inhaled 
glucocorticoids and exacerbations of COPD // N Engl J Med 2014;371:1285–94. 
124.
Köhnlein T, Windisch W, Köhler D, et al. Non-invasive positive pressure ventilation 
for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, 
multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698–705. 

жүктеу/скачать 1,6 Mb.

Достарыңызбен бөлісу: